Biogen's decision to halve price of Alzheimer's drug is ‘a day late and a dollar short,' says Raymond JamesMarket Watch • 12/20/21
Biogen to lower price of Alzheimer's drug aduhlem by 50% starting Jan. 1 to about $28,200 a yearMarket Watch • 12/20/21
Biogen Announces Reduced Price for ADUHELM® to Improve Access for Patients with Early Alzheimer's DiseaseGlobeNewsWire • 12/20/21
EMA's Committee Gives Thumbs Down To Biogen's Controversial Alzheimer's Drug, As ExpectedBenzinga • 12/17/21
Biogen and Eisai say EU regulatory committee adopted negative opinion for its Alzheimer's treatmentMarket Watch • 12/17/21
Biogen plans to start Phase 4 confirmatory study for Alzheimer's drug next yearMarket Watch • 12/16/21
Biogen and TheraPanacea Announce New Collaboration with the Potential to Advance Digital Health for Personalized Medicine in NeuroscienceGlobeNewsWire • 12/14/21
Biogen Inc. (BIIB) Dips More Than Broader Markets: What You Should KnowZacks Investment Research • 12/10/21
Sage Therapeutics and Biogen Announce New Analyses from the LANDSCAPE Clinical Development Program of Zuranolone in MDD Presented at the American College of Neuropsychopharmacology (ACNP) CongressBusiness Wire • 12/08/21
Biogen's Stock Price Currently Matches Intrinsic Value - Buy Their Pipeline For NothingSeeking Alpha • 12/07/21